An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

CompletedOBSERVATIONAL

Enrollment

17,847

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions

Chronic Kidney DiseaseType 2 Diabetes

Interventions

DRUG

Finerenone (Kerendia, BAY94-8862)

Retrospective cohort analysis using randomized clinical trials data.

DRUG

Sodium-glucose cotransporter-2 inhibitors (SGLT2i)

Retrospective cohort analysis using United States Optum Electronic Health Records data.

Trial Locations (1)

Bayer, Whippany